Jennifer Fricke
Family · Pasadena, CANPI 1902371057
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 305 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by AbbVie at 48.1% of the total. Reporting peaked in 2022 at $2,156 and has fallen 75.1% since, to $537 in 2025. Among family clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 305 payments — averaging $19.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Bristol Myers Squibb$456
- Takeda Pharmaceuticals U.S.A., Inc.$303
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$295
- Novartis$293
- Amgen$256
- plus $2K from 20 others
What the payments were for
- Food & beverage$6,090100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 148 | $2,929 |
| Bristol Myers Squibb | 29 | $456 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $303 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $295 |
| Novartis | 12 | $293 |
| Amgen | 14 | $256 |
| Gilead | 2 | $230 |
| Idorsia Pharmaceuticals US Inc | 13 | $202 |
| Lilly USA, LLC | 8 | $177 |
| Ardelyx, Inc. | 12 | $173 |
| Novo Nordisk | 7 | $164 |
| E.r. Squibb & Sons, L.L.C. | 2 | $120 |
| Sanofi | 3 | $79 |
| Regeneron Healthcare Solutions, Inc. | 4 | $68 |
| Boehringer Ingelheim | 2 | $44 |
| IBSA Pharma Inc. | 3 | $43 |
| GSK | 2 | $41 |
| Exact Sciences | 2 | $39 |
| Phathom Pharmaceuticals, Inc. | 2 | $38 |
| Redhill Biopharma Inc. | 2 | $29 |
| Bayer | 1 | $28 |
| Astellas Pharma US Inc | 1 | $24 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Bausch Health US, LLC | 1 | $16 |
| Genentech USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,090 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 32 | $249 |
| Methylprednisolone | 34 | $186 |
| Amlodipine Besylate | 26 | $151 |
| Doxycycline Hyclate | 25 | $145 |
| Escitalopram Oxalate | 20 | $137 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 17 | $133 |
| Ciprofloxacin Hcl | 20 | $127 |
| Azithromycin | 36 | $127 |
| Levothyroxine Sodium | 13 | $85 |
| Rosuvastatin Calcium | 39 | $74 |
| Metoprolol Succinate | 11 | $48 |
| Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide | 12 | $11 |
| PaxlovidNirmatrelvir/Ritonavir | 15 | $0 |
Paid to pharmacies, not to this prescriber.
Other family in Pasadena
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Erin DwyerSan Diego$189K
- Phyllis CasonLos Angeles$187K
- Gabriel SchwartzSan Francisco$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.